The role of the androgen receptor in triple-negative breast cancer Journal Article
| Authors: | Shah, P. D.; Gucalp, A.; Traina, T. A. |
| Article Title: | The role of the androgen receptor in triple-negative breast cancer |
| Abstract: | Greater than 70% of human breast cancers express the androgen receptor (AR). Emerging preclinical and clinical data suggest that AR may play a role in breast cancer pathogenesis and may serve as a therapeutic target in certain more difficult-to-treat breast cancer subtypes, such as triple-negative breast cancer. Although this is an area of active investigation, the clinical significance of this hormone receptor as a prognostic/predictive marker and its functional role in tumorigenesis is unclear. This review provides an update on the advances made in the last several years regarding the role of AR as a prognostic/predictive biomarker in breast cancer, the underlying biology of AR signaling in breast cancer development and the available clinical data for the use of androgen inhibition in the treatment of AR+ triple-negative breast cancer. © 2013 Future Medicine Ltd. |
| Keywords: | signal transduction; cancer survival; protein expression; protein phosphorylation; overall survival; promoter region; prednisone; fatigue; review; doxorubicin; placebo; drug efficacy; side effect; paclitaxel; protein conformation; protein domain; protein function; anorexia; protein analysis; biological markers; progression free survival; breast cancer; hepatocyte nuclear factor 3alpha; gene expression profiling; tumor volume; carboxy terminal sequence; protein degradation; nausea; protein binding; cyclophosphamide; antineoplastic activity; drug potency; tumor xenograft; breast neoplasms; cancer mortality; carcinogenesis; exemestane; dizziness; dyspnea; flushing; prostate cancer; gene expression regulation; heart palpitation; enzyme regulation; transcription regulation; androgen receptor; dimerization; receptor, erbb-2; receptors, estrogen; receptors, progesterone; hot flush; abiraterone acetate; bicalutamide; gonadorelin derivative; receptors, androgen; ligand binding; drug protein binding; genetic heterogeneity; castration resistant prostate cancer; triple negative breast cancer; triple-negative breast cancer; cancer prognosis; androgen receptor antagonists; enzalutamide; luminal ar; wnt7b protein |
| Journal Title: | Women's Health |
| Volume: | 9 |
| Issue: | 4 |
| ISSN: | 1745-5057 |
| Publisher: | Future Medicine |
| Date Published: | 2013-07-01 |
| Start Page: | 351 |
| End Page: | 360 |
| Language: | English |
| DOI: | 10.2217/whe.13.33 |
| PROVIDER: | scopus |
| PUBMED: | 23826776 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 August 2013" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work